These peptides may be of high clinical value with distinct applications to mitigate thrombotic microangiopathy (TMA), attenuate renal involvement in preeclampsia and antagonize severe renal side effects after systemic VEGF ablation (as seen in cancer treatment with anti-VEGF antibodies or inhibitors of VEGF receptors) [46,47,48,49]. This evidence concerns the gene VEGFA and cancer.